Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial
Michael D Kappelman,David A Wohl,Hans H Herfarth,Ann M Firestine,Jeremy Adler,Rana F Ammoury,Jeanine E Aronow,Dorsey M Bass,Julie A Bass,Keith Benkov,Catalina Berenblum Tobi,Margie E Boccieri,Brendan M Boyle,William B Brinkman,Jose M Cabera,Kelly Chun,Richard B Colletti,Cassandra M Dodds,Jill M Dorsey,Dawn R Ebach,Edurne Entrena,Christopher B Forrest,Joseph A Galanko,John E Grunow,Ajay S Gulati,Anastasia Ivanova,Traci W Jester,Jess L Kaplan,Subra Kugathasan,Mark E Kusek,Ian H Leibowitz,Tiffany M Linville,Ellen A Lipstein,Peter A Margolis,Phillip Minar,Zarela Molle-Rios,Jonathan Moses,Kelly K Olano,Lourdes Osaba,Pablo J Palomo,Helen Pappa,K T Park,Dinesh S Pashankar,Lisa Pitch,Michelle Robinson,Charles M Samson,Kelly C Sandberg,Julia R Schuchard,Michael Seid,Kimberly A Shelly,Steven J Steiner,Jennifer A Strople,Jillian S Sullivan,Jeanne Tung,Prateek Wali,Michael Zikry,Morris Weinberger,Shehzad A Saeed,Athos Bousvaros
DOI: https://doi.org/10.1053/j.gastro.2023.03.224
IF: 29.4
Gastroenterology
Abstract:Background & aims: Tumor necrosis factor inhibitors, including infliximab and adalimumab, are a mainstay of pediatric Crohn's disease therapy; however, nonresponse and loss of response are common. As combination therapy with methotrexate may improve response, we performed a multicenter, randomized, double-blind, placebo-controlled pragmatic trial to compare tumor necrosis factor inhibitors with oral methotrexate to tumor necrosis factor inhibitor monotherapy. Methods: Patients with pediatric Crohn's disease initiating infliximab or adalimumab were randomized in 1:1 allocation to methotrexate or placebo and followed for 12-36 months. The primary outcome was a composite indicator of treatment failure. Secondary outcomes included anti-drug antibodies and patient-reported outcomes of pain interference and fatigue. Adverse events (AEs) and serious AEs (SAEs) were collected. Results: Of 297 participants (mean age, 13.9 years, 35% were female), 156 were assigned to methotrexate (110 infliximab initiators and 46 adalimumab initiators) and 141 to placebo (102 infliximab initiators and 39 adalimumab initiators). In the overall population, time to treatment failure did not differ by study arm (hazard ratio, 0.69; 95% CI, 0.45-1.05). Among infliximab initiators, there were no differences between combination and monotherapy (hazard ratio, 0.93; 95% CI, 0.55-1.56). Among adalimumab initiators, combination therapy was associated with longer time to treatment failure (hazard ratio, 0.40; 95% CI, 0.19-0.81). A trend toward lower anti-drug antibody development in the combination therapy arm was not significant (infliximab: odds ratio, 0.72; 95% CI, 0.49-1.07; adalimumab: odds ratio, 0.71; 95% CI, 0.24-2.07). No differences in patient-reported outcomes were observed. Combination therapy resulted in more AEs but fewer SAEs. Conclusions: Among adalimumab but not infliximab initiators, patients with pediatric Crohn's disease treated with methotrexate combination therapy experienced a 2-fold reduction in treatment failure with a tolerable safety profile. Clinicaltrials: gov, Number: NCT02772965.